Carmen Díaz-Ortega

Carmen Díaz-Ortega

Auto-generated profile, based on publicly available information

Carmen Díaz-Ortega

Endocrinology Department, University Hospital of A Coruña, A Coruña (A Coruña), Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2021 in Endocrine
Verified
Journal Article
Closed access
PDF file
RVRocío Villar-Taibo
Rocío Villar-Taibo
CDC. Díaz-Ortega
C. Díaz-Ortega
MSMildred Sifontes-Dubon
Mildred Sifontes-Dubon
AFAntia Fernandez-Pombo
Antia Fernandez-Pombo
RSR. Serramito-García
R. Serramito-García
IMIgnacio Bernabeu Morón
Ignacio Bernabeu Morón

2 April 2020 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
David Araújo-VilarDavid Araújo-Vilar
David Araújo-Vilar
AFAntia Fernandez-Pombo
Antia Fernandez-Pombo
GCGemma Rodriguez Carnero
Gemma Rodriguez Carnero
MOMiguel Angel Martinez Olmos
Miguel Angel Martinez Olmos
ACAna Cantón
Ana Cantón
Sofía Sánchez-IglesiasSofía Sánchez-Iglesias
Sofía Sánchez-Iglesias
Background: Lipodystrophy syndromes are a group of disorders characterized by a loss of adipose tissue once other situations of nutritional deprivation or exacerbated catabolism have been ruled out. With the exception of the HIV-associated lipodystrophy, they have a very low prevalence, which together with their large phenotypic heterogeneity makes their identification difficult, even for endocrinologists and pediatricians. This leads to significant delays in diagnosis or even to misdiagnosis. Our group has developed an algorithm that identifies the more than 40 rare lipodystrophy subtypes described to date. This algorithm has been implemented in a free mobile application, LipoDDx®. Our aim was to establish the effectiveness of LipoDDx®. Forty clinical records of patients with a diagnosis of certainty of most lipodystrophy subtypes were analyzed, including subjects without lipodystrophy. The medical records, blinded for diagnosis, were evaluated by 13 physicians, 1 biochemist and 1 dentist. Each evaluator first gave his/her results based on his/her own criteria. Then, a second diagnosis was given using LipoDDx®. The results were analysed based on a score table according to the complexity of each case and the prevalence of the disease. Results: LipoDDx® provides a user-friendly environment, based on usually dichotomous questions or choice of clinical signs from drop-down menus. The final result provided by this app for a particular case can be a low/high probability of suffering a particular lipodystrophy subtype. Without using LipoDDx® the success rate was 17 ± 20%, while with LipoDDx® the success rate was 79 ± 20% (p < 0.01). Conclusions: LipoDDx® is a free app that enables the identification of subtypes of rare lipodystrophies, which in this small cohort has around 80% effectiveness, which will be of help to doctors who are not experts in this field. However, it will be necessary to analyze more cases in order to obtain a more accurate efficiency value.